Interferon Beta-1A
Interferon Beta-1A is a pharmaceutical drug with 43 clinical trials. Currently 3 active trials ongoing. Historical success rate of 85.7%.
Success Metrics
Based on 30 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
10
Mid Stage
20
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
83.3%
30 of 36 finished
16.7%
6 ended early
3
trials recruiting
43
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Trial of Treatments for COVID-19 in Hospitalized Adults
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Clinical Trials (43)
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Trial of Treatments for COVID-19 in Hospitalized Adults
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
Public Health Emergency: SOLIDARITY TRIAL Philippines
World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Interferon Beta 1a in Hospitalized COVID-19 Patients
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 43